Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?

Ciprian Tomuleasa, Andrei Cucuianu, Mihaela Aldea, Ioana Berindan-NeagoeResearch Center of Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaWe have read with great interest the study of Kim et al, recently published in the Inter...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5a06532947f34f448e28bf6648b245ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a06532947f34f448e28bf6648b245ac
record_format	dspace
spelling	oai:doaj.org-article:5a06532947f34f448e28bf6648b245ac2021-12-02T02:10:35ZSorafenib for the treatment of solid malignancies: what about the cancer microenvironment?1176-91141178-2013https://doaj.org/article/5a06532947f34f448e28bf6648b245ac2013-10-01T00:00:00Zhttp://www.dovepress.com/sorafenib-for-the-treatment-of-solid-malignancies-what-about-the-cance-a14770https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Ciprian Tomuleasa, Andrei Cucuianu, Mihaela Aldea, Ioana Berindan-NeagoeResearch Center of Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaWe have read with great interest the study of Kim et al, recently published in the International Journal of Nanomedicine.1 The physicians from South Korea describe the anti-tumor efficacy of sorafenib in cholangiocarcinoma, a malignancy with a dismal prognosis and refractory to most chemotherapy options. Surgery is the only curative option, but is limited to only a small number of cases due to the late diagnosis.2 This emphasizes the need to develop new approaches for such cases and the first potential new option is the tyrosine kinase inhibitor sorafenib, already proven to improve the therapeutic ratio of hepatocellular carcinoma, as according to Llovet et al.3 But unlike hepatocellular carcinoma, cholangiocarcinomas are epithelial cancers with a highly developed desmoplastic stroma due to the interaction between the cancer cell and the cancer associated fibroblasts (CAFs), as well as the macrophages, and the natural killer (NK) cells.4 This tumor microenvironment makes it difficult for a chemotherapy drug to reach the cancer cell and be efficient, which partially explains the reason why Kim et al1 developed a sorafenib-coated stent, that can be placed inside the biliary tree and deliver the drug continuously.View original paper by Kim and colleagues.Tomuleasa CCucuianu AAldea MBerindan-Neagoe IDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss Issue 1, Pp 4043-4044 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Tomuleasa C Cucuianu A Aldea M Berindan-Neagoe I Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
description	Ciprian Tomuleasa, Andrei Cucuianu, Mihaela Aldea, Ioana Berindan-NeagoeResearch Center of Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, RomaniaWe have read with great interest the study of Kim et al, recently published in the International Journal of Nanomedicine.1 The physicians from South Korea describe the anti-tumor efficacy of sorafenib in cholangiocarcinoma, a malignancy with a dismal prognosis and refractory to most chemotherapy options. Surgery is the only curative option, but is limited to only a small number of cases due to the late diagnosis.2 This emphasizes the need to develop new approaches for such cases and the first potential new option is the tyrosine kinase inhibitor sorafenib, already proven to improve the therapeutic ratio of hepatocellular carcinoma, as according to Llovet et al.3 But unlike hepatocellular carcinoma, cholangiocarcinomas are epithelial cancers with a highly developed desmoplastic stroma due to the interaction between the cancer cell and the cancer associated fibroblasts (CAFs), as well as the macrophages, and the natural killer (NK) cells.4 This tumor microenvironment makes it difficult for a chemotherapy drug to reach the cancer cell and be efficient, which partially explains the reason why Kim et al1 developed a sorafenib-coated stent, that can be placed inside the biliary tree and deliver the drug continuously.View original paper by Kim and colleagues.
format	article
author	Tomuleasa C Cucuianu A Aldea M Berindan-Neagoe I
author_facet	Tomuleasa C Cucuianu A Aldea M Berindan-Neagoe I
author_sort	Tomuleasa C
title	Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
title_short	Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
title_full	Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
title_fullStr	Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
title_full_unstemmed	Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
title_sort	sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/5a06532947f34f448e28bf6648b245ac
work_keys_str_mv	AT tomuleasac sorafenibforthetreatmentofsolidmalignancieswhataboutthecancermicroenvironment AT cucuianua sorafenibforthetreatmentofsolidmalignancieswhataboutthecancermicroenvironment AT aldeam sorafenibforthetreatmentofsolidmalignancieswhataboutthecancermicroenvironment AT berindanneagoei sorafenibforthetreatmentofsolidmalignancieswhataboutthecancermicroenvironment
_version_	1718402649494126592

Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?

Ejemplares similares